New Cannabinoid Extracted From Hemp: CBM

Find out everything about CBM, the newly found cannabinoid extracted from hemp.
02 October 2020
4 min read
New Cannabinoid Extracted From Hemp: CBM

  • 1. Cbm and insulin
  • 1. a. Ppars in medicine's spotlight
  • 2. Cbm growing into the market
  • 3. In conclusion

Marijuana has been a part of our lives for centuries, even millenniums, however, research on the subject has not been highly active until the last two decades when medical cannabis started gaining popularity. 

As far as we knew, the two most famous cannabinoid components in marijuana were THC and CBD. A new player has entered the medical marijuana game: we are talking about cannabimovone, or CBM. CBM can be found in a historical variety of hemp that was named Carmagnola after the name of a small village in Piedmont, Italy.

However, cannabimovone moved into the spotlight only recently ago when in March this year a group of Italian universities and research centers elaborated a study on the subject, which was published in an issue of Molecules.


CBM Molecule

Illustration of the cannabimovone molecule
But what exactly is cannabimovone? In this article we’re going to explain in detail the uses and characteristics of the newly found member of the cannabinoids family, CBM. 

CBM and Insulin

One of the most staggering aspects of cannabimovone involved the discovery of its possible benefits for the treatment of diabetes, metabolic disorders, and eating disorders.

“CBM promoted the expression of PPARγ target genes regulating the adipocyte differentiation and prevented palmitate‐induced insulin signaling impairment. Altogether, these results candidate CBM as a novel bioactive compound potentially useful for the treatment of insulin resistance‐related disorders.”1

“Overall, these findings support CBM as a new bioactive compound potentially useful for the treatment of insulin resistance disorders,” wrote the researchers.


Could CBM turn into a new alternative for diabetes treatments?

CBM could turn into a new alternative to treat diabetes and other metabolic disorders.

In simpler words, CBM might be an effective component to promote healthy insulin levels and metabolism for diabetic patients.

Technically speaking, CBM binds well with various receptors in the human body, particularly with a type of receptors called peroxisome proliferation-activated receptors, PPARα and PPARγ. These receptors are known for taking part in the regulation of hormone levels and internal organ cell generation in our bodies. PPARα and PPARγ also play a fundamental role in lipid metabolism, metabolic regulation, and energy homeostasis. 


For example, PPARα and PPARγ receptors control the genes that are in charge of cell production for our major organs, such as:

  • The heart;
  • Some muscles;
  • Liver;
  • Kidneys;
  • Pancreas;
  • Colon;
  • And spleen. 

CBM showed to react as an agonist of the PPARγ receptor, unlike the other components part of the cannabinoid family, THC and CBD which are antagonists of these receptors. 


Graphic abstract

Graphic abstract published in Molecules' issue.

PPARs in Medicine's Spotlight

In modern medicine, pharmaceutical drugs are often used for the treatment of a disease or disorder. But what happens when that illness is caused by defective, mutated, or damaged genes? In this case, it isn't recommended to treat the symptoms but to target the illness host. 

Given that PPARs directly control the genes that create and control a wide range of our vital cells, researches concluded that by exploiting these receptors they could target the host of eating disorders, hormone-related disorders, metabolic disorders, and different types of cancers. 2


There are already some PPARs-targeting drugs approved by the FDA and available in the US market. These medications however produce unwanted side effects like weight gain and heart issues.

While consuming cannabinoid products could possibly generate some weight gain due to the famous munchies, scientists could elaborate new formulations with cannabinoid combinations that produce small side effects and big therapeutic consequences. It’s all a matter of time, patience.

CBM Growing into the Market

As we've mentioned before, CBM comes mainly from the marijuana strain called Carmagnole, although once more research is done it is likely that this cannabinoid will be found in other strains. However, growing this strain is probably not a good business yet, taking into consideration that only a small amount of this cannabinoid is produced by the plant.


CannabinoidMedical Uses
THCAnxiety, glaucoma, insomnia, low appetite, muscle spasticity, nausea, pain and more.
CBDAnxiety, depression, inflammation, migraines, nausea, pain, mental disorders, seizures and more.
CBMDiabetes, metabolic disorders, eating disorders, hormone-related disorders, different types of cancers and more to discover.


Perhaps in a near-future breeders will perform back-crossing processes or line breeding with Carmagnola and start creating new strains that contain bigger amounts of cannabimovone. Or maybe bio technicians will be able to genetically manipulate bacteria, yeast, or even cannabis itself to develop high, industrial quantities of CBM.

Related story
Health benefits of CBD

In Conclusion

Medical cannabis investigations come along with many surprising and effective results for patients and therefore there should be no barriers for researchers to be able to keep making findings in such a reliable substance like a cannabinoid. 

The amazing discoveries about this new cannabinoid cannabimovone proved how imminent it is for researchers to dive into the cannabis field. After all, the study published in Molecules has proved that heavy health affections such as diabetes could be treated by new medication formulations containing cannabinoids like CBM, THC, CBD, THCV, or new cannabinoids discovered in the future. 


  1. "Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARγ Agonist via a Combined Computational and Functional Study." March 2020 - 
  2. "PPAR and immune system—what do we know?" July 2020 -
02 October 2020